ASCO 2022: Key Skin Cancer Studies

CME

Key Studies in Skin Cancer: Independent Conference Coverage of the 2022 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 29, 2022

Expiration: August 28, 2023

Allison Betof Warner
Allison Betof Warner, MD, PhD
Hussein Tawbi
Hussein Tawbi, MD

Activity

Progress
1
Course Completed

Hussein Tawbi, MD, PhD:
ASCO 2022 showed that we have made some definite progress in neoadjuvant therapy. The idea that we can start thinking about the extent of surgery and what regimens should be given in the adjuvant setting, if any, is really important. In the metastatic setting, the fact that we have a little more granularity on the relatlimab data in cutaneous melanoma is of interest. In addition, the activity of the camrelizumab/apatinib/temozolomide regimen in acral melanoma is really exciting. Those are my 3 big take-homes.

Allison Betof Warner, MD, PhD:
I agree with the study of camrelizumab/apatinib/temozolomide in acral melanoma. That is really exciting, and I think we will see a lot more with that regimen to come. I also think the updated data from KEYNOTE-716 on DMFS are really important and change our thinking about stage II melanoma. Adjuvant pembrolizumab is not just preventing locoregional recurrences, which are curable by surgery—it also is preventing distant metastasis.